Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells

In recent years, numerous new targeted drugs, including multi-kinase inhibitors and epigenetic modulators have been developed for cancer treatment. Ponatinib blocks a variety of tyrosine kinases including ABL and fibroblast growth factor receptor (FGFR), and the BET bromodomain (BRD) antagonists JQ1...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Karin, Berger, Daniela, Zielinski, Christoph C., Valent, Peter, Grunt, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995173/
https://www.ncbi.nlm.nih.gov/pubmed/29899872
http://dx.doi.org/10.18632/oncotarget.25474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995173/
https://www.ncbi.nlm.nih.gov/pubmed/29899872
http://dx.doi.org/10.18632/oncotarget.25474

Ejemplares similares